Bioanalytical Systems (BASI) Stock Price, News & Analysis

Company Overview

Bioanalytical Systems, Inc., doing business as Inotiv, provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. BioVaxys has an agreement with Inotiv to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.

Key Stats

• Today's Range: $1.55 to $1.66
• 50-Day Range: $14.04 to $22.50
• 52-Week Range: $3.05 to $21.08
• Volume: 97,514 shs
• Average Volume: 122,925 shs
• Market Capitalization: $17.59 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BASI Stock Analysis - Frequently Asked Questions

How were Bioanalytical Systems' earnings last quarter?

Bioanalytical Systems, Inc. (NASDAQ:BASI) issued its quarterly earnings data on Monday, February, 8th. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.16. The business earned $17.89 million during the quarter. Bioanalytical Systems had a negative net margin of 7.75% and a negative trailing twelve-month return on equity of 42.74%.
Read the conference call transcript.

What other stocks do shareholders of Bioanalytical Systems own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bioanalytical Systems investors own include Riot Platforms (RIOT), Boeing (BA), NVIDIA (NVDA), Overstock.com (OSTK), Enphase Energy (ENPH), Pure Storage (PSTG) and Mastercard (MA).

Company Calendar

• Last Earnings: 2/08/2021
• Today: 9/27/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Commercial Physical Research
• Sub-Industry: N/A
• Current Symbol: NASDAQ:BASI
• CUSIP: N/A
• CIK: 720154
• Web: www.basinc.com
• Phone: 765-463-4527
• Fax: N/A
• Employees: 397
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-4,680,000.00
• Net Margins: -7.75%
• Pretax Margin: N/A
• Return on Equity: -42.74%
• Return on Assets: -6.38%

Debt

• Debt-to-Equity Ratio: 2.49
• Current Ratio: 0.48
• Quick Ratio: 0.46

Sales & Book Value

• Annual Sales: $60.47 million
• Price / Sales: 0.28
• Cash Flow: $0.00 per share
• Price / Cash Flow: 558.40
• Book Value: $0.69 per share
• Price / Book: 2.23

Miscellaneous

• Outstanding Shares: 11,131,000
• Free Float: N/A
• Market Cap: $17.14 million
• Optionable: Not Optionable
• Beta: 1.92